Trial
NCT01334710
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Emory University
Collaborators
OSI Pharmaceuticals
Condition
Liver Cancer
Intervention
Sorafenib and OSI-906
Why stopped
safety issue observed on another hepatocellular study using OSI906
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-21